WASHINGTON – Ariad Pharmaceuticals Inc. will have a lot on the line Tuesday when an FDA advisory committee takes a hard look at the data for its sarcoma drug Taltorivc. But for the FDA, it all comes down to one question – do the risks outweigh the benefits?